Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Abstract Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient-reported outcomes (PROs) among adults and a...

Description complète

Détails bibliographiques

Auteurs principaux:	Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2024-05-01
Collection:	Dermatology and Therapy
Sujets:	Atopic dermatitis Itch Patient-reported outcome measures Quality of life Randomized controlled trials Upadacitinib
Accès en ligne:	https://doi.org/10.1007/s13555-024-01157-5
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!